---
title: "Pathway-specific polygenic risk scores identify biological mechanisms of cerebral small vessel dis"
id: "medrxiv-21-pathway-specific-polygenic-risk-scores-reveal-underlying-mechanisms-of-cerebral"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-21-pathway-specific-polygenic-risk-scores-reveal-underlying-mechanisms-of-cerebral"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.10.26360585v1?rss=1"
published_at: "2026-09-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pathway-specific polygenic risk scores identify biological mechanisms of cerebral small vessel dis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-21-pathway-specific-polygenic-risk-scores-reveal-underlying-mechanisms-of-cerebral
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.10.26360585v1?rss=1)
- **Published At:** 2026-09-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study generated and validated a global **polygenic risk score (PRS)** for white matter hyperintensities (**WMH**), a key MRI marker of **cerebral small vessel disease (cSVD)**, using the largest European-ancestry WMH GWAS (N=46,944) and UK Biobank MRI data (N=15,320; mean age 67). - The optimized global WMH-PRS explained additional variance in WMH in UK Biobank (delta-R-squared +4.1%, P=1.78e-193) and predicted WMH in independent cohorts across the lifespan: young adults (i-Share, N=1,578; age ~22), older community-dwellers (Three City-Dijon, N=1,443; age ~73), and memory-clinic patients (Memento, N=1,831; age ~71). - The WMH global-PRS associated with incident clinical outcomes in the UK Biobank (up to N=355,180): increased risk of incident stroke (overall, ischemic, and intracerebral hemorrhage) and incident all-cause dementia and vascular or mixed dementia subtype, but not Alzheimer's disease. - The authors constructed 3,794 pathway-specific PRS (ps-PRS) using canonical pathways from the Molecular Signatures Database (v2023.2) and applied permutation-based pathway enrichment in UKB-MRI to identify ps-PRS enriched for WMH. - They found 127 ps-PRS consistently enriched for WMH that clustered into ten biological domains; 61 of these (six clusters and 55 individual pathways) replicated in at least one external cohort (young, older community, or memory-clinic), with varying overlap across cohorts. - Secondary analyses highlighted four ps-PRS related to **lipid metabolism**, **ciliogenesis**, and **signal transduction** that were enriched in both young and older adults and associated with stroke and dementia; sphingolipid metabolism pathways were notable in the memory-clinic cohort. - Seven mostly lipid-related ps-PRS showed evidence of interaction with hypertension, suggesting vascular risk factors may modulate genetic pathway effects on WMH. - The study presents a multi-cohort ps-PRS framework revealing candidate biological pathways with differential associations across the lifespan and clinical outcomes, supporting potential targets for precision prevention and drug development for cSVD. - The work is a preprint and has not been peer reviewed; data access requires request to corresponding author and is not publicly available due to privacy considerations.
## Clinical Analysis & Structured Key Points
Pathway-specific polygenic risk scores reveal underlying mechanisms of cerebral small vessel disease | medRxiv Skip to main content Pathway-specific polygenic risk scores reveal underlying mechanisms of cerebral small vessel disease View ORCID Profile Tim D'Aoust , Ami Tsuchida , Carole Dufouil , Catherine Helmer , Philippe AMOUYEL , View ORCID Profile Jean-Charles Lambert , View ORCID Profile Quentin Le Grand , Stephanie Debette doi: https://doi.org/10.64898/2026.09.10.26360585 Tim D'Aoust 1 University of Bordeaux; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Tim D'Aoust Ami Tsuchida 1 University of Bordeaux; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carole Dufouil 1 University of Bordeaux; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Catherine Helmer 1 University of Bordeaux; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Philippe AMOUYEL 2 Univ Lille Inserm CHU Lille Institut Pasteur de Lille; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jean-Charles Lambert 3 INSERM, Institut Pasteur de Lille; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jean-Charles Lambert Quentin Le Grand 4 Inserm; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Quentin Le Grand For correspondence: quentin.le-grand{at}inserm.fr Stephanie Debette 5 Institut du Cerveau Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract White matter hyperintensities (WMH), a key MRI-marker of cerebral small vessel disease (cSVD), are common in older adults and associated with an increased risk of stroke and dementia. The latest WMH genome-wide association study (GWAS) identified 27 loci involving genes enriched for extracellular matrix, myelination, and membrane transport. Genetically predicted WMH correlates with white matter microstructural alterations in young adults and shows causal effects on stroke and dementia. However, biological pathways underlying WMH and their contribution to clinical outcomes remain unclear, and validated polygenic risk scores (PRS) for WMH are lacking. We applied global and pathway-specific PRS (ps-PRS) to generate robust WMH-PRS and identify biological pathways contributing to WMH across the lifespan. We leveraged the largest European-ancestry WMH-GWAS (N=46,944) and data from 15,320 UK Biobank participants with MRI (UKB-MRI) (mean age=67 (7.7) years) to optimize a WMH global-PRS and construct 3,794 ps-PRS based on canonical pathways from the Molecular Signatures Database (v2023.2). The best WMH global-PRS in UKB-MRI (P=1.78 x e-193; delta-R-squared=+4.1%) predicted WMH in independent cohorts: young adults (i-Share, N=1,578, age=22(2.3); P=0.0024; delta-R-squared=+0.5%), older community-dwellers (Three City-Dijon, N=1,443, age=73 (4.1); P=1.38xe-9; delta-R-squared=+2.2%), and memory-clinic patients (Memento, N=1,831, age=71 (8.5); P=1.11xe-19; delta-R-squared=+3.3%). In the UK Biobank (N up to 355,180), WMH global-PRS was associated with incident stroke (HR=1.06 [1.038, 1.082], P=2.6xe-8), including both ischemic stroke (HR=1.061[1.037, 1.086], P=1.6xe-8) and intracerebral hemorrhage (HR=1.083[1.026, 1.143], P=0.004). Higher global-PRS was also associated with incident all-cause dementia (HR=1.051 [1.030, 1.080], P=1xe-5) and its vascular or mixed dementia sub-type (HR=1.168[1.103, 1.237], P=1.1xe-7), but showed no association with Alzheimer's disease. Permutation-based pathway enrichment, performed in UKB-MRI, identified 127 ps-PRS consistently enriched for WMH and clustering into ten biological domains. Of these, 61 ps-PRS (six clusters and 55 individual pathways) were enriched in at least one follow-up cohort: 14 in older community-persons, 17 in young adults, and 37 in memory-clinic patients. Secondary analyses highlighted four ps-PRS involved in lipid metabolism, ciliogenesis, and signal transduction enriched in both young and older adults and associated with stroke and dementia. In the memory-clinic some ps-PRS, notably involved in sphingolipid metabolism, were also associated with dementia. Seven ps-PRS, mostly lipid-related, showed evidence of modulation by hypertension. In summary, we generated a validated WMH global-PRS showing robust association with cSVD clinical complications and introduce a multi-cohort WMH ps-PRS framework that reveals candidate biological pathways with differential associations across the lifespan and clinical outcomes. These findings may inform precision prevention and drug development for cSVD. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: 3C-Dijon: Ethics committee of the University Hospital of Kremlin-Bicetre gave ethical approval for this work. i-SHARE: The ethics committees of the Commission Nationale Informatique et Libertes (CNIL); CCTIRS (Comite Consultatif sur le Traitement de l'Information en matiere de Recherche dans le domaine de la Sante); CPP (Comite de Protection des Personnes); l'Agence Nationale de Securite du Medicament et Hors Produit de Sante (ANSM) gave ethical approval for this work. UK Biobank: The ethics committee of National Research Ethics Service Committee North West-Haydock (reference 48 11/NW/0382) gave ethical approval of this work. The MEMENTO cohort protocol has been approved by the local ethics committee (Comite de Protection des Personnes Sud-Ouest et Outre Mer III; approval number 2010-A01394-35) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to their containing information that could compromise the privacy of research participants. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 14, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Pathway-specific polygenic risk scores reveal underlying mechanisms of cerebral small vessel disease Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Pathway-specific polygenic risk scores reveal underlying mechanisms of cerebral small vessel disease Tim D'Aoust , Ami Tsuchida , Carole Dufouil , Catherine Helmer , Philippe AMOUYEL , Jean-Charles Lambert , Quentin Le Grand , Stephanie Debette medRxiv 2026.09.10.26360585; doi: https://doi.org/10.64898/2026.09.10.26360585 Share This Article: Copy Citation Tools Pathway-specific polygenic risk scores reveal underlying mechanisms of cerebral small vessel disease Tim D'Aoust , Ami Tsuchida , Carole Dufouil , Catherine Helmer , Philippe AMOUYEL , Jean-Charles Lambert , Quentin Le Grand , Stephanie Debette medRxiv 2026.09.10.26360585; doi: https://doi.org/10.64898/2026.09.10.26360585 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Epidemiology Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (901) Anesthesia (331) Cardiovascular Medicine (4809) Dentistry and Oral Medicine (479) Dermatology (414) Emergency Medicine (648) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1626) Epidemiology (15935) Forensic Medicine (32) Gastroenterology (1202) Genetic and Genomic Medicine (7043) Geriatric Medicine (733) Health Economics (1064) Health Informatics (5041) Health Policy (1433) Health Systems and Quality Improvement (1760) Hematology (584) HIV/AIDS (1344) Infectious Diseases (except HIV/AIDS) (16287) Intensive Care and Critical Care Medicine (1173) Medical Education (668) Medical Ethics (154) Nephrology (722) Neurology (7270) Nursing (366) Nutrition (1081) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3606) Ophthalmology (1051) Orthopedics (397) Otolaryngology (454) Pain Medicine (470) Palliative Medicine (139) Pathology (707) Pediatrics (1797) Pharmacology and Therapeutics (737) Primary Care Research (766) Psychiatry and Clinical Psychology (5890) Public and Global Health (9748) Radiology and Imaging (2417) Rehabilitation Medicine and Physical Therapy (1450) Respiratory Medicine (1247) Rheumatology (640) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (776) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Pre-diagnostic 1-year prevalence of polypharmacy and PIMcog in Norwegian outpatients with MCI or d](https://medichelpline.com/clinical-feed/plos-one-14-one-year-pre-diagnostic-prevalence-and-associated-factors-of-polypharmacy-and.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Estrogen-only menopausal therapy associated with reduced Alzheimer’s biomarkers](https://medichelpline.com/clinical-feed/medical-news-today-0-estrogen-only-therapy-after-menopause-linked-to-reduced-alzheimer-s-biomarkers.md)
- [Avoiding smoking, diabetes, and high blood pressure in midlife may add up to 13 dementia-free years](https://medichelpline.com/clinical-feed/medical-news-today-0-avoiding-3-risk-factors-in-midlife-could-add-13-dementia-free-years.md)
- [Stopping Statins at Age 75 in Low‑Risk Adults: French Trial Found No Increase in Deaths](https://medichelpline.com/clinical-feed/stat-news-0-stopping-statins-in-people-over-75-at-low-risk-for-heart-disease-didn-t.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.